Prof. Yohann Loriot (Université Paris-Saclay, France) discussed novel treatment options beyond immunotherapy . He urged that a better understanding of the tumour biology is necessary to identify new targets, and will facilitate precision medicine.
Approaches derived from fundamental tumour biology have demonstrated clinical efficacy, including fibroblast growth factor receptor (FGFR) inhibitors and antibody-drug conjugates. In muscle-invasive bladder cancer (MIBC), somatic genetic alterations are potentially targetable, including mutations in *FGFR3*, *HHRm*, *HER2*, components of angiogenesis, and the epigenome.
*FGFR3*-mutation is associated with luminal-papillary urothelial carcinoma; 70% of this pathology harbours somatic activating mutations, 20% exhibits gene rearrangement, and 10% overexpresses *FGFR3*. Specific FGFR inhibitors tested in urothelial cancer include BGJ398, rogaratinib, and erdafitinib. In the BLC2001 phase 2 trial, 99 heavil...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Adofaragene firadenovec effective in BCG-unresponsive papillary NMIBC: phase 3 results Next Article
KEYNOTE-436 QoL same for both arms in mRCC »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.